{
    "hands_on_practices": [
        {
            "introduction": "Clinical decision-making for pancreatic cysts rarely relies on a single test; instead, it requires synthesizing multiple, sometimes conflicting, data points. This exercise  simulates a common and challenging scenario where different diagnostic markers provide countervailing evidence. By applying Bayesian reasoning through the use of likelihood ratios, you will learn to formally update a pre-test clinical suspicion by integrating data from sources like cyst fluid chemistry and cytology to arrive at a more robust posterior probability of malignancy.",
            "id": "5107868",
            "problem": "A patient with a pancreatic cyst undergoes endoscopic ultrasound-guided fine-needle aspiration. Cyst fluid laboratory evaluation demonstrates carcinoembryonic antigen (CEA) of $50$ ng/mL, amylase of $12{,}000$ U/L, and cytology showing mucin-producing epithelium. Intraductal Papillary Mucinous Neoplasm (IPMN) is a mucinous cystic neoplasm that often communicates with the pancreatic ductal system. Carcinoembryonic antigen (CEA) is commonly used to differentiate mucinous from non-mucinous cysts, and cyst fluid amylase reflects ductal communication. For clinical decision-making in systemic surgery, assume that, for the target state of IPMN, the following independent binary test results have the stated positive likelihood ratios: $\\text{LR}^{+}_{\\text{CEA}<192\\ \\text{ng/mL}}=0.4$, $\\text{LR}^{+}_{\\text{amylase}>5000\\ \\text{U/L}}=3$, and $\\text{LR}^{+}_{\\text{mucin cytology}}=4$. Assume a prior probability $P(\\text{IPMN})=0.5$ based on pretest clinical assessment.\n\nUsing first principles of probabilistic inference for diagnostic tests appropriate to surgical decision-making, reconcile the low CEA with mucinous features in a brief mechanistic rationale, and compute the posterior probability $P(\\text{IPMN}\\mid \\text{all tests positive as defined})$. Express the final posterior probability as a decimal and round your answer to four significant figures.",
            "solution": "The problem statement is evaluated as valid. It is scientifically grounded in the clinical context of pancreatic surgery, well-posed with sufficient and consistent information for a unique solution, and phrased objectively. The task requires both a qualitative mechanistic explanation and a quantitative probabilistic calculation, both of which are fully specified.\n\nThe problem requires a two-part response: a mechanistic reconciliation of the patient's test results and a calculation of the posterior probability of Intraductal Papillary Mucinous Neoplasm (IPMN).\n\nFirst, the mechanistic rationale will be addressed. The patient presents with seemingly contradictory findings: a low cyst fluid carcinoembryonic antigen (CEA) level of $50$ ng/mL, which according to the provided likelihood ratio for $\\text{CEA} < 192$ ng/mL ($\\text{LR}^{+} = 0.4$), reduces the probability of IPMN. However, the patient also has cytology positive for mucin-producing epithelium ($\\text{LR}^{+} = 4$) and a very high cyst fluid amylase level of $12{,}000$ U/L ($\\text{LR}^{+} = 3$ for amylase $> 5000$ U/L), both of which increase the probability of IPMN.\n\nThe key to reconciling these findings lies in the pathophysiology of IPMN, as hinted at in the problem statement. IPMNs, particularly main-duct or mixed-type variants, often communicate with the main pancreatic ductal system. Cyst fluid amylase is a marker for this communication. The extremely high amylase level in this patient ($12{,}000$ U/L) is strong evidence of such a communication. This ductal connection allows for the influx of pancreatic juice, which is rich in amylase but contains negligible CEA, into the cyst. The CEA within the cyst is produced by the mucinous epithelium lining the cyst wall. The influx of pancreatic juice dilutes the CEA concentration within the cyst fluid. Therefore, a true mucinous neoplasm such as an IPMN can paradoxically exhibit a low CEA level if significant ductal communication and subsequent dilution are present. The positive cytology for mucin-producing cells confirms the underlying mucinous nature of the neoplasm, while the high amylase explains the mechanism for the diluted, low CEA level.\n\nSecond, the posterior probability $P(\\text{IPMN}\\mid \\text{all tests positive})$ will be computed. We begin from the first principles of probabilistic inference, specifically Bayes' theorem expressed in the odds-likelihood ratio formulation. The relationship is:\n$$\n\\text{Posterior Odds} = \\text{Prior Odds} \\times \\text{Total Likelihood Ratio}\n$$\nThe prior probability of IPMN is given as $P(\\text{IPMN}) = 0.5$. The prior odds are calculated as:\n$$\n\\text{Odds}(\\text{IPMN}) = \\frac{P(\\text{IPMN})}{1 - P(\\text{IPMN})} = \\frac{0.5}{1 - 0.5} = 1\n$$\nThe problem states that the three diagnostic tests are independent. Therefore, the total likelihood ratio ($\\text{LR}_{\\text{total}}$) is the product of the individual likelihood ratios corresponding to the patient's test results. The patient's results are:\n1.  CEA level of $50$ ng/mL. This result falls under the category $\\text{CEA} < 192$ ng/mL, for which the likelihood ratio is $\\text{LR}^{+}_{\\text{CEA}} = 0.4$.\n2.  Amylase level of $12{,}000$ U/L. This result falls under the category $\\text{amylase} > 5000$ U/L, for which the likelihood ratio is $\\text{LR}^{+}_{\\text{amylase}} = 3$.\n3.  Cytology shows mucin-producing epithelium. This corresponds to the positive mucin cytology test, for which the likelihood ratio is $\\text{LR}^{+}_{\\text{cytology}} = 4$.\n\nThe total likelihood ratio is the product of these individual likelihood ratios:\n$$\n\\text{LR}_{\\text{total}} = \\text{LR}^{+}_{\\text{CEA}} \\times \\text{LR}^{+}_{\\text{amylase}} \\times \\text{LR}^{+}_{\\text{cytology}} = 0.4 \\times 3 \\times 4\n$$\n$$\n\\text{LR}_{\\text{total}} = 1.2 \\times 4 = 4.8\n$$\nNow, we can calculate the posterior odds of IPMN given these three test results:\n$$\n\\text{Odds}(\\text{IPMN} \\mid \\text{tests}) = \\text{Odds}(\\text{IPMN}) \\times \\text{LR}_{\\text{total}} = 1 \\times 4.8 = 4.8\n$$\nFinally, we convert the posterior odds back to a posterior probability. The formula for converting odds to probability is:\n$$\nP(\\text{A}) = \\frac{\\text{Odds}(\\text{A})}{1 + \\text{Odds}(\\text{A})}\n$$\nApplying this to our posterior odds:\n$$\nP(\\text{IPMN} \\mid \\text{tests}) = \\frac{\\text{Odds}(\\text{IPMN} \\mid \\text{tests})}{1 + \\text{Odds}(\\text{IPMN} \\mid \\text{tests})} = \\frac{4.8}{1 + 4.8} = \\frac{4.8}{5.8}\n$$\nThis simplifies to the fraction $\\frac{48}{58} = \\frac{24}{29}$. To provide the answer as a decimal rounded to four significant figures:\n$$\nP(\\text{IPMN} \\mid \\text{tests}) = \\frac{24}{29} \\approx 0.8275862...\n$$\nRounding to four significant figures gives $0.8276$. Despite the low CEA suggesting against IPMN, the strong positive evidence from the high amylase and mucinous cytology decisively increases the post-test probability from $0.5$ to approximately $0.8276$.",
            "answer": "$$\n\\boxed{0.8276}\n$$"
        },
        {
            "introduction": "Once a decision for non-operative surveillance of a pancreatic cyst is made, the key question becomes: what is the patient's risk of progression over time? This practice  introduces the fundamental tools of survival analysis to answer this question quantitatively. Starting from the core definition of an instantaneous hazard function, you will derive the cumulative risk of progression, providing a solid mathematical foundation for understanding and communicating the prognosis of patients in a surveillance program.",
            "id": "5107849",
            "problem": "A patient with a branch-duct intraductal papillary mucinous neoplasm (IPMN) of diameter $2.5$ $\\mathrm{cm}$ and no mural nodules is enrolled in nonoperative surveillance. Assume the time to clinically significant progression $T$ is a nonnegative, continuous random variable with an instantaneous hazard function $h(t)$ that is constant over time and equal to $0.02$ $\\mathrm{year}^{-1}$, consistent with a stable annual hazard attributable to the lesion phenotype in the absence of high-risk stigmata. Under the standard survival analysis framework that relates the hazard function $h(t)$ to the survival function $S(t) = \\Pr(T \\ge t)$, derive the cumulative risk of progression $F(t) = \\Pr(T < t)$ over $t = 5$ years from first principles, starting only from the definitions of the hazard function and survival function, and assuming no competing risks and independence from other time-varying covariates. Compute the resulting numerical value of the $5$-year cumulative risk and express your final answer as a decimal fraction rounded to four significant figures. Do not use a percentage sign.",
            "solution": "The problem requires the derivation of the cumulative risk of progression for a patient with a specific type of pancreatic neoplasm, based on a constant hazard rate, and its calculation over a specified time interval. The derivation must start from first principles, specifically the definitions of the hazard and survival functions.\n\nThe time to clinically significant progression, $T$, is a nonnegative, continuous random variable. The survival function, $S(t)$, is defined as the probability that the event of interest (progression) has not occurred by time $t$. Mathematically, this is:\n$$ S(t) = \\Pr(T \\ge t) $$\nThe instantaneous hazard function, $h(t)$, represents the instantaneous rate of progression at time $t$, given that the patient has not progressed up to time $t$. Its formal definition is:\n$$ h(t) = \\lim_{\\Delta t \\to 0} \\frac{\\Pr(t \\le T < t + \\Delta t \\mid T \\ge t)}{\\Delta t} $$\nUsing the definition of conditional probability, $\\Pr(A \\mid B) = \\frac{\\Pr(A \\cap B)}{\\Pr(B)}$, we can rewrite the numerator:\n$$ \\Pr(t \\le T < t + \\Delta t \\mid T \\ge t) = \\frac{\\Pr(\\{t \\le T < t + \\Delta t\\} \\cap \\{T \\ge t\\})}{\\Pr(T \\ge t)} $$\nThe intersection of the event that progression occurs in the interval $[t, t+\\Delta t)$ and the event that progression has not occurred before $t$ is simply the event that progression occurs in $[t, t+\\Delta t)$. So, we have:\n$$ \\Pr(t \\le T < t + \\Delta t) = \\Pr(T \\ge t) - \\Pr(T \\ge t + \\Delta t) = S(t) - S(t + \\Delta t) $$\nSubstituting this back into the expression for the conditional probability:\n$$ \\Pr(t \\le T < t + \\Delta t \\mid T \\ge t) = \\frac{S(t) - S(t + \\Delta t)}{S(t)} $$\nNow, we substitute this into the definition of the hazard function:\n$$ h(t) = \\lim_{\\Delta t \\to 0} \\frac{S(t) - S(t + \\Delta t)}{\\Delta t \\cdot S(t)} = \\frac{1}{S(t)} \\lim_{\\Delta t \\to 0} \\frac{S(t) - S(t + \\Delta t)}{\\Delta t} $$\nThe limit is the definition of the negative of the derivative of $S(t)$ with respect to $t$. That is, $\\frac{dS(t)}{dt} = \\lim_{\\Delta t \\to 0} \\frac{S(t + \\Delta t) - S(t)}{\\Delta t}$. Therefore:\n$$ h(t) = -\\frac{1}{S(t)} \\frac{dS(t)}{dt} $$\nThis establishes the fundamental differential equation relating the hazard function and the survival function. We can rearrange this equation to solve for $S(t)$:\n$$ \\frac{dS(t)}{S(t)} = -h(t) dt $$\nWe integrate both sides of this equation from time $0$ to an arbitrary time $t$. The integration variable is changed to $\\tau$ to avoid confusion with the upper limit of integration.\n$$ \\int_{S(0)}^{S(t)} \\frac{1}{S(\\tau)} dS(\\tau) = -\\int_{0}^{t} h(\\tau) d\\tau $$\nThe left-hand side integrates to $\\ln(S(t)) - \\ln(S(0))$. At time $t=0$, the patient has, by definition, not yet progressed, so the probability of survival up to time $0$ is certain: $S(0) = \\Pr(T \\ge 0) = 1$. Since $\\ln(1) = 0$, the equation simplifies to:\n$$ \\ln(S(t)) = -\\int_{0}^{t} h(\\tau) d\\tau $$\nTo find the survival function $S(t)$, we exponentiate both sides:\n$$ S(t) = \\exp\\left(-\\int_{0}^{t} h(\\tau) d\\tau\\right) $$\nThis is the general expression for the survival function in terms of the hazard function.\n\nThe problem states that the hazard function is constant over time, $h(t) = h = 0.02$ $\\mathrm{year}^{-1}$. We substitute this into the integral:\n$$ \\int_{0}^{t} h(\\tau) d\\tau = \\int_{0}^{t} h d\\tau = h \\int_{0}^{t} d\\tau = ht $$\nThe survival function therefore takes the form of an exponential decay:\n$$ S(t) = \\exp(-ht) $$\nThe problem asks for the cumulative risk of progression, $F(t)$, which is the cumulative distribution function (CDF) of the random variable $T$. It is defined as $F(t) = \\Pr(T < t)$. By the law of total probability, the probability of progression before time $t$ and the probability of surviving to at least time $t$ must sum to $1$:\n$$ F(t) + S(t) = \\Pr(T < t) + \\Pr(T \\ge t) = 1 $$\nThus, the cumulative risk is given by:\n$$ F(t) = 1 - S(t) $$\nSubstituting our derived expression for $S(t)$ gives the final formula for the cumulative risk:\n$$ F(t) = 1 - \\exp(-ht) $$\nWe are asked to compute this value for $t = 5$ years, with the constant hazard rate $h = 0.02$ $\\mathrm{year}^{-1}$. The product $ht$ is dimensionless, as required for the argument of the exponential function: $(0.02$ $\\mathrm{year}^{-1}) \\times (5$ $\\mathrm{year}) = 0.1$.\nSubstituting the numerical values into the formula for $F(t)$:\n$$ F(5) = 1 - \\exp(-0.02 \\times 5) $$\n$$ F(5) = 1 - \\exp(-0.1) $$\nNow, we compute the numerical value:\n$$ \\exp(-0.1) \\approx 0.904837418 $$\n$$ F(5) \\approx 1 - 0.904837418 = 0.095162582 $$\nThe problem requires the answer to be expressed as a decimal fraction rounded to four significant figures.\nThe first significant figure is $9$, the second is $5$, the third is $1$, and the fourth is $6$. The fifth significant figure is $2$, which is less than $5$, so we round down (i.e., truncate at the fourth significant figure).\n$$ F(5) \\approx 0.09516 $$\nThe clinical information regarding the IPMN diameter of $2.5$ $\\mathrm{cm}$ and the absence of mural nodules is consistent with the low, constant hazard rate provided, as these are features of a low-risk lesion suitable for surveillance. This information serves to contextualize and validate the problem but does not enter the mathematical calculation directly.",
            "answer": "$$\n\\boxed{0.09516}\n$$"
        },
        {
            "introduction": "The management of branch-duct IPMN often balances the upfront risks of surgery against the long-term risk of malignant transformation. This hands-on practice  delves into formal decision analysis, challenging you to determine the precise threshold of malignancy prevalence at which one strategy becomes dominant over another. By calculating and comparing the expected values of outcomes like quality-adjusted life years ($QALYs$) and costs, you will gain insight into how quantitative thresholds that inform clinical guidelines are established.",
            "id": "5107831",
            "problem": "A surgeon must decide between immediate oncologic resection and active surveillance for a patient with a branch-duct intraductal papillary mucinous neoplasm (IPMN) without high-risk stigmata. Let the unobserved prevalence of malignancy at the time of decision be $p \\in [0,1]$. The decision is modeled with expected values of quality-adjusted life years (QALYs) and direct medical costs. Use the following scientifically plausible and simplified parameters, and assume independence of events and that all given numbers are already time-discounted present values over the relevant horizon.\n\nOutcomes for resection:\n- Perioperative mortality probability $d_{R} = 0.02$.\n- If pathology is benign and the patient survives surgery, expected utility $Q_{B}^{R} = 9.6$ QALYs (derived from a $10.0$ QALYs baseline minus a surgery disutility of $0.4$ QALYs).\n- If pathology is malignant and the patient survives surgery, expected utility $Q_{M}^{R} = 7.0$ QALYs.\n- Base cost of resection $C_{R0} = \\$80{,}000$, plus additional adjuvant treatment cost $C_{A} = \\$30{,}000$ if pathology is malignant.\n\nOutcomes for surveillance:\n- If the lesion is benign, expected utility $Q_{B}^{S} = 10.0$ QALYs.\n- If the lesion is malignant (present at decision time but not immediately resected), expected utility $Q_{M}^{S} = 2.0$ QALYs.\n- Present value of a structured surveillance program cost $C_{S0} = \\$7{,}000$.\n- If the lesion is malignant under surveillance, downstream advanced cancer management cost $C_{M} = \\$120{,}000$.\n\nUsing only the definition of expected value for utilities and costs, and treating $p$ as the only variable in a one-way sensitivity analysis, determine the malignancy prevalence threshold $p^{\\ast}$ at which surveillance becomes dominant over resection, where “dominant” is defined as simultaneously having strictly greater expected QALYs and strictly lower expected costs than resection. Express your final answer as a pure probability (a decimal between $0$ and $1$) and round to four significant figures.",
            "solution": "The problem requires the determination of a malignancy prevalence threshold, denoted as $p^{\\ast}$, for a branch-duct intraductal papillary mucinous neoplasm (IPMN). Below this threshold, a strategy of active surveillance is dominant over immediate oncologic resection. Dominance is defined as having both strictly greater expected quality-adjusted life years (QALYs) and strictly lower expected direct medical costs.\n\nFirst, we must formulate the expressions for the expected utility (QALYs) and expected cost for each of the two strategies: resection (R) and surveillance (S). These will be functions of the unknown prevalence of malignancy, $p$.\n\nLet $E[QALY_R](p)$ and $E[Cost_R](p)$ be the expected QALYs and cost for the resection strategy, respectively. Let $E[QALY_S](p)$ and $E[Cost_S](p)$ be the corresponding expected values for the surveillance strategy.\n\nFor the resection strategy (R):\nThe probability of the lesion being malignant is $p$, and the probability of it being benign is $(1-p)$. The perioperative mortality is $d_R = 0.02$, so the probability of surviving the surgery is $(1-d_R) = 1 - 0.02 = 0.98$. We assume a utility of $0$ QALYs in the event of perioperative death.\n\nThe expected QALYs for resection is a weighted average over the outcomes:\n$E[QALY_R](p) = p \\cdot ( (1-d_R) Q_M^R + d_R \\cdot 0 ) + (1-p) \\cdot ( (1-d_R) Q_B^R + d_R \\cdot 0 )$\n$E[QALY_R](p) = (1-d_R) \\left[ p Q_M^R + (1-p) Q_B^R \\right]$\nSubstituting the given values:\n$E[QALY_R](p) = (1-0.02) \\left[ p \\cdot 7.0 + (1-p) \\cdot 9.6 \\right]$\n$E[QALY_R](p) = 0.98 \\left[ 7.0p + 9.6 - 9.6p \\right]$\n$E[QALY_R](p) = 0.98 \\left[ 9.6 - 2.6p \\right]$\n$E[QALY_R](p) = 9.408 - 2.548p$\n\nThe expected cost for resection depends on whether adjuvant therapy is needed:\n$E[Cost_R](p) = p \\cdot (C_{R0} + C_A) + (1-p) \\cdot C_{R0}$\n$E[Cost_R](p) = p C_{R0} + p C_A + C_{R0} - p C_{R0}$\n$E[Cost_R](p) = C_{R0} + p C_A$\nSubstituting the given values:\n$E[Cost_R](p) = 80{,}000 + p \\cdot 30{,}000$\n\nFor the surveillance strategy (S):\nThe expected QALYs for surveillance is a direct weighted average of the outcomes for malignant and benign cases:\n$E[QALY_S](p) = p \\cdot Q_M^S + (1-p) \\cdot Q_B^S$\nSubstituting the given values:\n$E[QALY_S](p) = p \\cdot 2.0 + (1-p) \\cdot 10.0$\n$E[QALY_S](p) = 2.0p + 10.0 - 10.0p$\n$E[QALY_S](p) = 10.0 - 8.0p$\n\nThe expected cost for surveillance depends on whether downstream advanced cancer management is needed:\n$E[Cost_S](p) = p \\cdot (C_{S0} + C_M) + (1-p) \\cdot C_{S0}$\n$E[Cost_S](p) = p C_{S0} + p C_M + C_{S0} - p C_{S0}$\n$E[Cost_S](p) = C_{S0} + p C_M$\nSubstituting the given values:\n$E[Cost_S](p) = 7{,}000 + p \\cdot 120{,}000$\n\nAccording to the problem, surveillance is dominant over resection if both of the following strict inequalities are met:\n1. $E[QALY_S](p) > E[QALY_R](p)$\n2. $E[Cost_S](p) < E[Cost_R](p)$\n\nWe will solve each inequality for $p$ to find the range of prevalence where each condition holds.\n\nCondition 1 (QALYs):\n$10.0 - 8.0p > 9.408 - 2.548p$\n$10.0 - 9.408 > 8.0p - 2.548p$\n$0.592 > 5.452p$\n$p < \\frac{0.592}{5.452}$\nLet's define the QALY threshold as $p_Q$:\n$p_Q = \\frac{0.592}{5.452} \\approx 0.108584...$\nSo, for $p < p_Q$, surveillance yields higher expected QALYs.\n\nCondition 2 (Costs):\n$7{,}000 + 120{,}000p < 80{,}000 + 30{,}000p$\n$120{,}000p - 30{,}000p < 80{,}000 - 7{,}000$\n$90{,}000p < 73{,}000$\n$p < \\frac{73{,}000}{90{,}000}$\nLet's define the cost threshold as $p_C$:\n$p_C = \\frac{73}{90} \\approx 0.811111...$\nSo, for $p < p_C$, surveillance has lower expected costs.\n\nFor surveillance to be the dominant strategy, both conditions must be satisfied simultaneously. This means $p$ must be less than both $p_Q$ and $p_C$:\n$p < p_Q \\quad \\text{and} \\quad p < p_C$\nThis is equivalent to the single condition:\n$p < \\min(p_Q, p_C)$\n\nThe threshold $p^{\\ast}$ at which surveillance *becomes* dominant is the boundary of this region. Thus, $p^{\\ast}$ is this minimum value.\n$p^{\\ast} = \\min \\left( \\frac{0.592}{5.452}, \\frac{73}{90} \\right)$\n$p^{\\ast} = \\min(0.108584..., 0.811111...)$\n$p^{\\ast} = 0.108584...$\n\nThe problem requires the answer to be rounded to four significant figures.\n$p^{\\ast} \\approx 0.1086$\n\nThis threshold $p^{\\ast}$ represents the point of indifference for the more restrictive of the two conditions, which in this case is the utility (QALYs). For any prevalence of malignancy $p < 0.1086$, surveillance is strictly preferred in terms of both expected QALYs and expected cost, making it the dominant strategy.",
            "answer": "$$\\boxed{0.1086}$$"
        }
    ]
}